Accium BioSciences Appoints Dr. Nenad Sarapa to its Scientific Advisory Board.

SEATTLE -- Accium BioSciences, Inc. announced today the appointment of Dr. Nenad Sarapa to the company's Scientific Advisory Board. Dr. Sarapa is currently the Senior Director and Global Head of Translational Medicine at Daiichi Medical Research in Park Ridge, New Jersey. He is a recognized expert in the design of microdosing and Exploratory IND studies.

Dr. Sarapa is Board Certified in Clinical Pharmacology and Therapeutics. After leaving medical practice in 1994, Dr. Sarapa served as a senior clinical research physician and director of clinical pharmacology at several companies including Glaxo Wellcome, Pharmacia, and Pfizer. He has published numerous articles in pharmacokinetics, clinical pharmacology, cardiovascular safety and early human microdosing.

"We are very pleased to have Dr. Sarapa join Accium's Scientific Advisory Board," commented Dr. Glenn Kawasaki, Chief Executive Officer of Accium BioSciences. "Dr. Sarapa's extensive knowledge and experience in developing cost-effective strategies for translation of compounds into the clinic will broaden the scope of methods and applications of Accium's services."

Accium BioSciences is the first U.S. specialty CRO to offer bioanalytical services based on accelerator mass spectrometry (AMS), an extremely sensitive detection platform that permits quantitation of drugs and metabolites in a wide range of biological samples, including samples obtained in very early clinical trials.

"I am excited to provide scientific assistance in the expansion of accelerator mass spectrometry methods in preclinical and clinical testing," said Dr. Sarapa. "Accium provides pharmaceutical researchers a high quality commercial source of AMS bioanalytical services in the United States." He added, "This is a technology that should decrease the cost and effort in early drug development and improve the selection of promising compounds before formal Phase 1 testing in the clinic. The valuable potential of AMS microdosing for picking winners and decreasing late-phase attrition is acknowledged by the FDA in its recently released Exploratory IND guidance."

About Accium BioSciences

Accium BioSciences is a specialty contract research organization that offers highly sensitive bioanalytical services with a focus on early-stage drug development. The company facility includes the only commercial Accelerator Mass Spectrometer (AMS) in the U.S. Using AMS, researchers obtain pharmacokinetics, bioavailability and metabolite profiles of new drug candidates earlier in the drug development process. For more information, please visit www.acciumbio.com.